Several strategies indirectly targeting the stability of N-Myc derived from this PTM regulatory mechanism, such as a ROCK2 small-molecule inhibitor, can activate the phosphorylation ability of Gsk3β on threonine-58 of N-Myc and therefore reinforce the degradation of N-Myc conducted by Fbxw7, resulting in downregulating N-Myc protein levels and suppressing the growth of MYCN-amplified NB cells in vivo (36). The gene discussed is GSK3B; the disease is neuroblastoma.